6/13/2023 0 Comments Als stem cell treatment 2015![]() “It is not a process where you get everything you want – you sometimes get impurities, so we have a method and patent to take the right cells and put them in the patient. ![]() In fact, Kadimastem is the only cell therapy company with this capability. Kadimastem is also developing technology to purify non-relevant cells from the production procedure by selecting the right cells to put in the patient. In mice, we were able to show the dose escalating needed in order to achieve normal glycaemia, so we know most of the things that we need to know about these cells.” “In diabetes, we have managed to demonstrate that we have the capability to manufacture the islets in a good, reproducible way and our proof-of-concept studies show that our cells are capable of ameliorating glycaemia in diabetic animals. “We anticipate that in about two years our diabetes product will be in clinical trials,” says Molakandov. In April 2021, the company announced it had secured $6.8 million in financing to expedite its research and development programmes. The company aims to test multiple injections of AstroRx cells in the next round of clinical trials to try to prolong the beneficial effect.įor IsletRx, Kadimastem is working with global regulatory authorities to start pre-clinical studies this year. The study results show a high safety profile of AstroRx cells and also demonstrated that this particular approach significantly decreased the progression of the disease for three months after AstroRx administration, when measured by ALS Functional Rating Scale-Revised (ALSFRS-S). In March 2021, the company completed a Phase 1/2a clinical trial at Jerusalem’s Hadassah Medical Center, which validated safety and efficacy. The astrocyte cells are injected directly into the cerebrospinal cord fluid of the patients to support the dying motor neurons in the brain and spinal cord of ALS patients and slow progression of the disease. Kadimastem’s lead product for ALS, AstroRx, is a cell therapy product containing astrocytes derived from human embryonic stem cells. We just accelerate the process that takes place in utero over nine months and follow the same stages in a shorter time period.” We have ways to maneuver stem cells to the destination and target tissue we want. “We see the cells like clay in our hands that we manipulate in culture and mimic development processes. “Any tissue in the body can be made from the stem cells as they are immature, very easy to work with cells and can proliferate as much as we want to become whatever we want,” says Molakandov. After developing treatments for multiple sclerosis, he turned his focus to two main disease areas – diabetes and ALS. You have to calculate everything from how much you eat, the amount of insulin to inject, and how much physical exercise to take – everything has to be managed! With our therapy, we aim to make it easy by simply putting the functional cells in the patient,” Molakandov tells pharmaphorum.įounded in 2009 by Kadimastem’s chief scientist Professor Michel Revel, the therapy is based on stem cell research from Israel’s Weizmann Institute of Science, looking at the potential of restoring activity lost in tissues due to disease damage. “Diabetes is a very hard disease to manage, especially with young children. Using micro-encapsulation technology, integrated within IsletRx, the islet cells are protected from attack by the host immune system. The product in development, IsletRx, is clinical grade pancreatic islet cells which produce and secrete insulin and glucagon in response to blood glucose levels. The Tel-Aviv listed company is leading research and development of a cell therapy comprising functional pancreatic islet cells. Every donor is different, and if you offer a therapy, it should be good, reliable, consistent, and the same for everyone.”Īs the head of diabetes research at Israeli cell therapy company Kadimastem, Molakandov believes they could have the next major diabetes therapy. “But even if there were enough donor islets, the standardisation of this therapy is horrible. “Only a few thousand people have benefited from this therapy as there are not enough donors,” says Kfir Molakandov. But years later, the potential of islet therapy is yet to be realised due to difficulties finding donors and harvesting cells. In the 1990s, when the first transplant of islets took place, it was hailed as the cure for diabetes. Catherine Longworth spoke with Kadimastem’s head of diabetes research, Kfir Molakandov to find out more. Israeli company Kadimastem is developing regenerative medicine therapies based on differentiated cells derived from human embryonic stem cells to treat diseases such as Amyotrophic lateral sclerosis (ALS) and diabetes.
0 Comments
Leave a Reply. |